|
Antimicrobial susceptibility (percentage) of Gram-positive bacteria causing bloodstream infection |
||||||
| Drug |
S. aureus |
E. faecium* |
E. faecalis* |
|||
|
|
||||||
| CA 13 |
HA 17 |
CA 12 |
HA 9 |
CA 9 |
HA 6 |
|
|
|
||||||
| Penicillin |
0 |
0 |
10 |
0 |
17 |
75 |
| Ampicillin* |
- |
- |
25 |
11 |
100 |
100 |
| Amoxicillin-clavulanate |
77 |
50 |
70 |
11† |
100 |
100 |
| Cloxacillin |
92 |
88 |
- |
- |
- |
- |
| Cefuroxime |
92 |
88 |
- |
- |
- |
- |
| Ceftazidime |
85 |
80 |
- |
- |
- |
- |
| Meropenem |
100 |
100 |
- |
- |
- |
- |
| Gentamicin* |
100 |
81 |
67 |
33 |
56 |
67 |
| Vancomycin* |
100 |
100 |
100 |
100 |
100 |
100 |
| Erythromycin |
100 |
71 |
0 |
0 |
22 |
33 |
| Doxycycline |
62 |
35 |
9 |
0 |
25 |
0 |
| Co-trimoxazole |
69 |
63 |
27 |
0 |
67 |
40 |
| Chloramphenicol |
85 |
73 |
50 |
11 |
38 |
33 |
| Ciprofloxacin* |
77 |
81 |
42 |
22 |
100 |
100 |
| Linezolid* |
- |
- |
100 |
100 |
100 |
100 |
| Quinupristin-dalfopristin* |
- |
- |
100 |
100 |
0 |
17 |
|
CA, community-acquired infection; HA, hospital-acquired infection; "-", not done. *E-test was used for susceptibility testing of enterococci against ampicillin, ciprofloxacillin, linezolid, quinupristin-dalfopristin, vancomycin and high-level gentamicin resistance. † Statistically significant difference in susceptibility among hospital-acquired and community-acquired isolates, p < 0.05 by two-sided Fisher's exact test. | ||||||
Blomberg et al. BMC Infectious Diseases 2007 7:43 doi:10.1186/1471-2334-7-43 |
||||||